293 related articles for article (PubMed ID: 32472655)
1. Cytokine storm in COVID-19 and parthenolide: Preclinical evidence.
Bahrami M; Kamalinejad M; Latifi SA; Seif F; Dadmehr M
Phytother Res; 2020 Oct; 34(10):2429-2430. PubMed ID: 32472655
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory activity of parthenolide-depleted Feverfew (Tanacetum parthenium).
Sur R; Martin K; Liebel F; Lyte P; Shapiro S; Southall M
Inflammopharmacology; 2009 Feb; 17(1):42-9. PubMed ID: 19112586
[TBL] [Abstract][Full Text] [Related]
3. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
4. The Antiviral, Anti-Inflammatory Effects of Natural Medicinal Herbs and Mushrooms and SARS-CoV-2 Infection.
Shahzad F; Anderson D; Najafzadeh M
Nutrients; 2020 Aug; 12(9):. PubMed ID: 32854262
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
6. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19.
Berretta AA; Silveira MAD; Cóndor Capcha JM; De Jong D
Biomed Pharmacother; 2020 Nov; 131():110622. PubMed ID: 32890967
[TBL] [Abstract][Full Text] [Related]
7. COVID-19: consider cytokine storm syndromes and immunosuppression.
Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
[No Abstract] [Full Text] [Related]
8. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase.
Kwok BH; Koh B; Ndubuisi MI; Elofsson M; Crews CM
Chem Biol; 2001 Aug; 8(8):759-66. PubMed ID: 11514225
[TBL] [Abstract][Full Text] [Related]
9. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.
Beyazit F; Beyazit Y; Tanoglu A; Haznedaroglu IC
Med Hypotheses; 2020 Oct; 143():110150. PubMed ID: 32763660
[TBL] [Abstract][Full Text] [Related]
10. Targeting inflammation and cytokine storm in COVID-19.
Huang Q; Wu X; Zheng X; Luo S; Xu S; Weng J
Pharmacol Res; 2020 Sep; 159():105051. PubMed ID: 32603772
[No Abstract] [Full Text] [Related]
11. Tackling the cytokine storm in COVID-19, challenges and hopes.
Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
[TBL] [Abstract][Full Text] [Related]
12. Feverfew extracts and the sesquiterpene lactone parthenolide inhibit intercellular adhesion molecule-1 expression in human synovial fibroblasts.
Piela-Smith TH; Liu X
Cell Immunol; 2001 May; 209(2):89-96. PubMed ID: 11446741
[TBL] [Abstract][Full Text] [Related]
13. Cautions and Opportunities for Botanicals in COVID-19 Patients: A Comment on the Position of the French Agency for Food, Environmental and Occupational Health & Safety.
Firenzuoli F; Antonelli M; Donelli D; Gensini GF; Maggini V
J Altern Complement Med; 2020 Oct; 26(10):851-853. PubMed ID: 32960104
[No Abstract] [Full Text] [Related]
14. Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications.
Haimei MA
Clin Appl Thromb Hemost; 2020; 26():1076029620944497. PubMed ID: 32722927
[TBL] [Abstract][Full Text] [Related]
15. Bromelain: A Review on its Potential as a Therapy for the Management of Covid-19.
Owoyele BV; Bakare AO; Ologe MO
Niger J Physiol Sci; 2020 Jun; 35(1):10-19. PubMed ID: 33084621
[TBL] [Abstract][Full Text] [Related]
16. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322
[TBL] [Abstract][Full Text] [Related]
17. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.
Alunno A; Carubbi F; Rodríguez-Carrio J
RMD Open; 2020 May; 6(1):. PubMed ID: 32423970
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 and Diabetes: The Importance of Controlling RAGE.
De Francesco EM; Vella V; Belfiore A
Front Endocrinol (Lausanne); 2020; 11():526. PubMed ID: 32760352
[No Abstract] [Full Text] [Related]
19. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
20. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
Dalamaga M; Karampela I; Mantzoros CS
Metabolism; 2020 Aug; 109():154282. PubMed ID: 32497535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
